12.07.2015 Views

medical and biological sciences - Collegium Medicum - Uniwersytet ...

medical and biological sciences - Collegium Medicum - Uniwersytet ...

medical and biological sciences - Collegium Medicum - Uniwersytet ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

40Natalia Kruszewska, Jan Styczynski2004-2008 w Klinice Pediatrii, Hematologii i Onkologii.146/305 pacjentów było urodzonych przed 1995 rokiem.Przeanalizowano obecność w surowicy krwi markerów zakażeniawirusami HBV i HCV oznaczonych w trakcie hospitalizacji.Zakażenie HBV rozpoznawano na podstawie obecnościantygenu HBsAg lub przeciwciał anty-HBc-IgM, natomiastzakażenie HCV na podstawie obecności przeciwciałanty-HCV.W y n i k i . W badanej grupie 305 dzieci u 3 (0,98%)stwierdzono zakażenie wirusem HBV, wszyscy należeli dogrupy urodzonych przed 1995 rokiem. We wszystkich przypadkachzakażenia wykryto przed przyjęciem do Kliniki,przy czym 2/3 zakażonych pacjentów pochodziło z innychośrodków. Ponadto u 150/159 (94,3%) dzieci objętych programemszczepień stwierdzono obecność przeciwciał anty-HBs; w 72 przypadkach stężenie ochronne. U 4 (1,3%) pacjentówstwierdzono zakażenie wirusem HCV: u 3 urodzonychprzed 1995 rokiem i u 1 urodzonego później. U 3/4dzieci zakażenie nastąpiło w trakcie terapii.Wnioski. (1) Wprowadzenie szczepień ochronnychprzeciwko zakażeniom HBV przyczyniło się do opanowaniaendemii zakażeń HBV wśród dzieci z chorobami nowotworowymi.(2) Równocześnie odsetek zakażeń HCV w tejgrupie pacjentów uległ obniżeniu, co przemawia za dużymznaczeniem również niespecyficznych metod profilaktycznych.(3) Aktualne ryzyko zakażenia HBV i HCV w trakcieterapii przeciwnowotworowej jest porównywalne z ryzykiemw populacji ogólnej.Key words: HBV, HCV, vaccination, cancer, children, epidemiologySłowa kluczowe: HBV, HCV, szczepienia, nowotwór, dzieci, epidemiologiaINTRODUCTIONChildren with malignancy carry a high risk of hepatitisB virus (HBV) <strong>and</strong> hepatitis C virus (HCV) infections.Factors that promote the infections include: frequentcontact with a highly endemic environment dueto many hospitalizations, all necessary diagnostic <strong>and</strong>therapeutic manipulations that injure tissues [1,2].Immunosuppression <strong>and</strong> treatment harmful to liverwhich patients have to undergo, might cause an unfavorableprogression of hepatitis. Although hepatitis isusually asymptomatic during anticancer treatment, itcan rapidly progress to fulminant type after cessationof chemotherapy <strong>and</strong> cause liver necrosis with hepaticcoma [2]. A high rate of the infection might progressto the chronic phase, which is further associated withthe development of liver cirrhosis <strong>and</strong> hepatocellularcarcinoma [3]. Thus, HBV <strong>and</strong> HCV infections canplay an adverse prognostic role in criteria of diseasefreesurvival [4]. It can essentially abolish the effectsof treatment of the basic disease or become the finalcause of death [3].Prior to 1995, viral hepatitis infections among childrenwith cancer were a serious clinical problem inPol<strong>and</strong>. At that time, HBV infections were found in62,2% of oncological patients in our clinic, while54,3% were infected with HCV [1]. This situationforced introduction of many prophylactic methods,which included the use of new-generation disposalequipment, strict hygienic rules in nursing patients,proper blood donors screening, <strong>and</strong> specific passive<strong>and</strong> active immunization [2].Apart from that, an obligatory vaccination of allneonates in Pol<strong>and</strong> was introduced. It started in 1994<strong>and</strong> covered the whole country in 1996. It was introducedin the Bydgoszcz area in the beginning of 1995[3].The aim of this study was to analyze the presentepidemiology of HBV <strong>and</strong> HCV infections amongchildren with malignancy, with respect to m<strong>and</strong>atoryvaccination program against HBV of neonates <strong>and</strong>infants introduced in 1995.MATERIALS AND PATIENTSA retrospective study was carried out in 305 childrenwith malignant diseases that were hospitalizedbetween August 2004 <strong>and</strong> January 2008 in the Chair<strong>and</strong> Clinic of Pediatric Hematology <strong>and</strong> Oncology inBydgoszcz, Pol<strong>and</strong>. 146 patients out of 305 (48%)were born prior to 1995. The remaining 159 (52%)patients were born in 1995 or later <strong>and</strong> had thereforebeen immunized according to m<strong>and</strong>atory vaccinationschedule (3 doses of vaccine administrated during thefirst days of life, <strong>and</strong> then in 2 nd <strong>and</strong> 6 th month afterbirth). The patients were diagnosed as follows: leukemia122 (40%), lymphoma 57 (19%), brain tumors 31(10%), nephroblastoma 18 (6%), <strong>and</strong> other solid tumors(25%).All patients were screened for hepatitis B <strong>and</strong> C virusesby testing for the presence of HBsAg, anti-HBs,anti-HBe, HBeAg, anti-HBc-IgM, anti-HBc-IgG <strong>and</strong>anti-HCV in serum. The tests were performed at thebeginning of the first admission to the hospital <strong>and</strong>were then repeated during further therapy. A patient

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!